Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
about
Bispecific antibodies and their applicationsEffective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression levelAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorCCR9 in cancer: oncogenic role and therapeutic targetingSecond-generation inhibitors of Bruton tyrosine kinaseAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Immunotherapy in hematologic malignancies: past, present, and future.Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient.Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.New development in CAR-T cell therapy.Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemiaABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabImmunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab.The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.Recent advances of bispecific antibodies in solid tumors.Syk inhibitors in clinical development for hematological malignancies.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Cancer immunotherapy beyond immune checkpoint inhibitors.Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins.Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.Bispecific antibodies: design, therapy, perspectives.Bone marrow stromal cells enhance the survival of chronic lymphocytic leukemia cells by regulating HES-1 gene expression and H3K27me3 demethylation.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Immuno-Oncology: Emerging Targets and Combination Therapies
P2860
Q26774024-ABE07EC7-2224-4BC6-8483-F3F65D1FED7FQ27300701-CCB9C906-8CA7-420D-8DE7-388876134063Q28066316-4E70AC5F-E6B7-41DF-848D-230B73D91096Q28066712-2D3E173F-B36C-48F8-96D0-23B85527B3E0Q28076118-398D477B-8E2F-4B79-9194-B7CC59394E28Q30275229-841643E9-A60E-4A3F-9880-AC044DF8BD4BQ33593865-1E805A05-918A-410E-A3DA-0E183C81E309Q36591877-C2D1D164-939B-4C3E-98D2-1290205B7245Q37012569-A6CDF7E1-3A2F-4D06-8B85-3387F701D1E6Q37119773-BC5FC6FE-F35E-4557-9AE7-050238D3D843Q37129564-2E5E93C1-1EA9-4E0B-8DFA-0D8A23044D14Q37615772-75D67B86-6DA7-46E9-A56A-B61C72B72FFCQ37619710-95FFB10E-FE5B-4489-9629-FF8549D4C9AAQ37658246-A232E85E-0465-4874-91E2-9D25BEAB0913Q37708939-6F41A719-4260-415C-A417-CBD221C28F24Q38558611-42771C9C-CEA8-4C0C-AA96-292419F86551Q38640263-F8168644-E51B-4E22-A38D-6D0165A27173Q38640917-688586EC-AE9B-4D38-9E6B-1744341313A9Q38759986-7F023B25-9529-451D-A92C-8AF0A47E670AQ38989496-1F1AABD9-E6E2-4159-8D25-02191534F42AQ41048538-87CA0F11-C5DD-4947-8641-B1426EA906ABQ41149154-7024FFE0-38A1-411A-ADA5-ADFB31F819F1Q41264328-DA0950AC-E63A-42EA-8A92-0505DB7FA7A9Q41696278-FF2695DC-4AFF-4D93-BC94-CB847C90AE3EQ42011012-E19F8017-5C44-4838-92C4-21F473CA4D8DQ47103332-A220C4F3-1269-4786-9625-1FAA69EE60C5Q47554248-DEAF2264-CD76-47E3-A951-C10CBB4A419EQ48187016-09E71C7A-487C-4735-8453-A5F3A5B50CEAQ48226662-243ECF11-ADB3-41A4-A3FA-0CDE65061CC8Q49195146-8515FA54-E322-4D14-9373-99BF8206026FQ49592081-5E2534EC-6B42-48FB-BBC5-2B162742C823Q49878390-B8D1751B-049D-42BE-A35C-3E886B120089Q55216327-79241766-936B-422F-99F3-79EF54798C1AQ56889817-9CD02982-516B-4AF1-A912-E20ECBEACE7A
P2860
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@ast
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@en
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@nl
type
label
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@ast
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@en
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@nl
prefLabel
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@ast
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@en
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@nl
P2093
P2860
P921
P3181
P1476
Blinatumomab: a bispecific T c ...... actory acute lymphoid leukemia
@en
P2093
Delong Liu
Jiaping Fu
Jingjing Wu
Mingzhi Zhang
P2860
P2888
P3181
P356
10.1186/S13045-015-0195-4
P407
P5008
P577
2015-09-04T00:00:00Z
P5875
P6179
1047120600